store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Combretastatin A-1 is a potent microtubule inhibitor with anti-tumour and anti-vascular activity, acting through microtubule protein depolymerisation-mediated inactivation of AKT to inhibit the Wnt/β-catenin pathway, and can be used to study hepatocellular carcinoma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 49.00 | |
2 mg | 5 days | $ 71.00 | |
5 mg | In stock | $ 199.00 |
Description | Combretastatin A-1 is a potent microtubule inhibitor with anti-tumour and anti-vascular activity, acting through microtubule protein depolymerisation-mediated inactivation of AKT to inhibit the Wnt/β-catenin pathway, and can be used to study hepatocellular carcinoma. |
Targets&IC50 | A375:61 nM, LM-3:33.8 nM, HepG2 cells:9.2 nM, MCF-7 cells:46.0 nM, CT-26:1075 nM, Huh7:728.2 nM, NCI-1975:256.3 nM, MDA-MB-231 cells:17.6 nM, Bel-7402:38.4 nM, BGC-803:12.2 nM, Hepa 1-6:32.9 nM, Smmc 7721 cells:12.8 nM |
In vitro | Combretastatin A-1 (CA1P) induces apoptosis of TAMs in vitro through the same mechanism observed in HepG2 cells, and it eliminates TAMs in the tumor microenvironment (TME) in vivo. Combretastatin A-1 (1-10 nM; 24 hours) induces AKT inactivation and removal of GSK-3β inhibition by microtubule depolymerization, leading to HepG2 cell apoptosis [2]. Combretastatin A-1 (1-50 nM; 6 hours) reduces the mitochondrial membrane potential (MMP) of HepG2 cells and induces the accumulation of ROS in a dose-dependent manner [3]. |
In vivo |
In the HepG2 subcutaneous xenograft model, Combretastatin A-1 (1-4 mg/kg; i.v. every other day for 4 weeks) significantly reduces the tumor volume [3]. In the orthotopic hepatocellular carcinoma mouse model, Combretastatin A-1 (2 mg/kg; every other day for 21 days) demonstrates enhanced apoptosis [3]. |
Synonyms | Combretastatin A1 |
Molecular Weight | 332.35 |
Formula | C18H20O6 |
CAS No. | 109971-63-3 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (240.71 mM), Sonication is recommended.
DMF: 5 mg/mL
Ethanol: 3 mg/mL
DMSO:PBS (pH 7.2) (1:1): 0.5 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Combretastatin A-1 109971-63-3 Cytoskeletal Signaling PI3K/Akt/mTOR signaling Akt Microtubule Associated Combretastatin A 1 Combretastatin A1 inhibitor inhibit